Clover Health Investments, Corp
Here’s whether Clover Health Investments, Corp (CLOV) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+8.57% over 10 days); RSI 36 — healthy momentum range; strong 1-year return of +40.5%; 3-month momentum positive (+77.8%). Concerns: below the 50-day MA (medium-term momentum negative); declining volume on rally — weak conviction (0.64x 30d avg). Currently 22.7% off its 52-week high. Score: +4/7.
CLOV is holding above its long-term 200-day MA ($2.94) but has slipped below the 50-day MA ($4.44), pointing to short-term weakness in an otherwise intact trend. An RSI of 35.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +40.5% compares to +16.5% for SPY (beat the market by 24.0%). The current 22.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.